Horst Lindhofer Selected Research

Horst Lindhofer Research Topics

Disease

34	Neoplasms (Cancer) 01/2022 - 02/2002
12	Ascites 06/2014 - 11/2005
7	Melanoma (Melanoma, Malignant) 01/2017 - 02/2004
5	Ovarian Neoplasms (Ovarian Cancer) 07/2014 - 07/2007
4	Peritoneal Neoplasms 01/2018 - 11/2005
3	Carcinoma (Carcinomatosis) 01/2012 - 05/2010
2	Neuroblastoma 01/2022 - 01/2021
2	Stomach Neoplasms (Stomach Cancer) 01/2018 - 11/2010
2	Nausea 01/2018 - 02/2009
2	Abdominal Pain (Pain, Abdominal) 01/2018 - 01/2011
2	Fever (Fevers) 01/2011 - 02/2009
2	Lymphoma (Lymphomas) 05/2010 - 02/2002
2	Breast Neoplasms (Breast Cancer) 05/2009 - 05/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2008 - 02/2006
2	Residual Neoplasm 08/2008 - 02/2006
1	Non-Muscle Invasive Bladder Neoplasms 09/2021
1	Infections 01/2018
1	Ovarian Epithelial Carcinoma 07/2014
1	Vomiting 01/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011
1	Malignant Pleural Effusion 02/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2007
1	Body Weight (Weight, Body) 01/2007
1	Lymphopenia (Lymphocytopenia) 05/2006
1	Experimental Melanoma 02/2006
1	Neoplasm Micrometastasis 11/2005
1	B-Cell Lymphoma (Lymphoma, B Cell) 02/2002

Drug/Important Bio-Agent (IBA)

17	Epithelial Cell Adhesion MoleculeIBA 10/2021 - 11/2005
16	catumaxomabIBA 10/2021 - 07/2007
12	AntibodiesIBA 01/2022 - 02/2004
11	AntigensIBA 01/2022 - 02/2002
9	Bispecific AntibodiesIBA 01/2017 - 11/2005
5	Immunoglobulin G (IgG)IBA 01/2022 - 05/2010
4	CytokinesIBA 01/2021 - 02/2004
3	Immunoglobulin Fc FragmentsIBA 01/2021 - 08/2012
3	EnzymesIBA 01/2018 - 05/2006
3	GangliosidesIBA 11/2012 - 02/2004
3	ertumaxomabIBA 05/2010 - 05/2006
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
2	dinutuximabIBA 01/2022 - 01/2021
2	GD2 gangliosideIBA 08/2015 - 08/2012
2	Immunoglobulins (Immunoglobulin)IBA 01/2012 - 02/2009
2	Monoclonal AntibodiesIBA 02/2009 - 10/2007
1	Immune Checkpoint ProteinsIBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Cytostatic AgentsIBA 09/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	IpilimumabIBA 01/2017
1	PlatinumIBA 07/2014
1	Biomarkers (Surrogate Marker)IBA 06/2014
1	AvidinIBA 06/2013
1	Biotin (Vitamin H)FDA Link 06/2013
1	ParaffinIBA 06/2013
1	9-O-acetyl-GD3 gangliosideIBA 11/2012
1	Peptides (Polypeptides)IBA 08/2012
1	InterferonsIBA 08/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	CD3 ComplexIBA 10/2010
1	Hepatitis B e AntigensIBA 05/2010
1	Trastuzumab (Herceptin)FDA Link 05/2009
1	human ERBB2 proteinIBA 05/2009
1	InterleukinsIBA 08/2008
1	Sodium Chloride FDA LinkGeneric 01/2007
1	Prednisolone (Predate)FDA LinkGeneric 11/2005
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 11/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2005
1	PerforinIBA 02/2004
1	Proteoglycans (Proteoglycan)IBA 02/2004
1	Neoplasm Antigens (Tumor Antigens)IBA 02/2002

Therapy/Procedure

15	Therapeutics 01/2022 - 02/2002
10	Immunotherapy 08/2015 - 11/2005
3	Drug Therapy (Chemotherapy) 07/2014 - 02/2009
2	Aftercare (After-Treatment) 01/2012 - 02/2009
1	Intravesical Administration 09/2021
1	Intravenous Administration 08/2015